An open‐label, crossover study of a new phosphate‐binding agent in haemodialysis patients: ferric citrate

Abstract

Ferric citrate shows promise as a means of lowering the serum phosphate concentration in haemodialysis patients. Further studies are needed to find the optimal dose.